Citadel Advisors’s Anebulo Pharmaceuticals ANEB Stock Holding History

Citadel Advisors’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,239	Closed	-$24.5K	–	12913
2025 Q4	$24.5K	Buy	+24,239	New	+$55.3K	﹤0.01%	12285
2025 Q3	–	Sell	-25,017	Closed	-$36K	–	12685
2025 Q2	$36K	Buy	25,017 +13,848	+124%	+$15.8K	﹤0.01%	11918
2025 Q1	$14.5K	Buy	+11,169	New	+$16.4K	﹤0.01%	13359

Citadel Advisors's ANEB Position: Q1 2026 in Review

Citadel Advisors sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 24,239 shares — an estimated $24.5K sold.

Citadel Advisors first reported a position in ANEB in Q1 2025 and held it in 3 quarters. The position peaked at $36K in Q2 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

Citadel Advisors reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 24,239 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $24.5K.
Citadel Advisors first reported a position in Anebulo Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Citadel Advisors's Anebulo Pharmaceuticals position peaked at $36K in Q2 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.